New study verifies the value

RNS Number : 2220G

Deltex Medical Group PLC

28 January 2010

 



Deltex Medical Group plc

New study verifies the value of CardioQ-ODM™ 

28 January 2010 - Deltex Medical Group plc ("Deltex Medical" or the "Company"), the global leader in oesophageal Doppler monitoring ("ODM"), notes the publication of a new study indicating the value of CardioQ-ODM system in moderate as well as high risk surgery.

Doctors from the University of Copenhagen1 in Denmark used the CardioQ-ODM to assess the prevalence of intravascular volume deficit in 60 patients. The patients were divided into three groups: 20 patients undergoing major open abdominal surgery, 20 patients undergoing moderate surgery (radical prostatectomy) and 20 patients undergoing relatively minor surgery (mastectomy) with only reasonably healthy patients included in the last two groups.

The study found that: overall 70% of patients had a functional fluid deficit and therefore responded to CardioQ-ODM guided fluid management; that there was no significant difference in the prevalence of such a deficit between the groups and that the largest deficit occurred in one of the patients undergoing the relatively minor procedure.

1Functional intravascular volume deficit in patients before surgery. M. Bundgaard-Nielsen, C Jorgensen, N Secher, H Kehlet. ACTA ANAESTHESIOLOGICA SCANDINAVICA December 2009 

Ewan Phillips, Deltex Medical's chief executive, commented:

"This is an important, statistically significant, study from the world leader in fast track surgery. It confirms the importance of CardioQ-ODM guided fluid management for patients undergoing moderate as well as major surgery."

For further information, please contact:-

Deltex Medical Group plc            01243 774 837

Nigel Keen, Chairman                    [e-mail]

Ewan Phillips, Chief Executive        [e-mail]

Paul Mitchell, Finance Director       [e-mail]

Nominated Adviser & Broker

Arden Partners plc                      020 7614 5900

Chris Hardie                                 [e-mail]

Matthew Armitt                             [e-mail]

Kreab Gavin Anderson               020 7554 1400

Deborah Walter                            [e-mail]

Robert Speed                               [e-mail]

  Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODM™ monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier.

The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay.

There are already nearly 2,000 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 200 clinical publications on the use of the CardioQ-ODM which have repeatedly:-

• Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works

• Proved that the CardioQ-ODM works in a wide range of surgical procedures

• Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients.

The SupraQ™ is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.

 

END

 

 

NRAKKODDPBKDFDB